Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html


Study Counts

Type Study_count
Total_Studies 921
interventional 859
Observational 59
Registry 3

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type Study_Count
Drug 343
Drug|Radiation 108
Biological 49
Biological|Drug 39
Drug|Procedure 35
Drug|Other 29
Device 21
Radiation 19
Other 16
Drug|Other|Radiation 15
Procedure 13
Drug|Procedure|Radiation 12
Drug|Other|Procedure 11
Device|Drug 10
Biological|Drug|Other 9
Drug|placebo 8
Biological|Drug|Radiation 7
Biological|Other 7
Biological|Other|Procedure 7
Behavioral 6
Biological|Drug|Procedure 6
Drug|placebo|Radiation 6
Biological|Procedure 5
Drug|Other|Procedure|Radiation 5
Procedure|Radiation 5
Biological|Drug|placebo 4
Device|Drug|Radiation 4
Diagnostic Test 4
Biological|Drug|Other|Procedure 3
Biological|Drug|Other|Procedure|Radiation 3
Combination Product 3
Device|Drug|Other 3
Device|Drug|Procedure 3
Dietary Supplement 3
Dietary Supplement|Drug 3
Drug|Genetic|Other 3
Other|Procedure 3
Biological|placebo 2
Biological|Radiation 2
Drug|Genetic|Other|Procedure 2
Drug|Genetic|Other|Procedure|Radiation 2
Behavioral|Drug 1
Behavioral|Radiation 1
Biological|Device|Drug 1
Biological|Device|Other 1
Biological|Drug|Genetic|Other 1
Biological|Drug|Other|placebo|Radiation 1
Biological|Drug|Other|Radiation 1
Biological|Drug|placebo|Procedure|Radiation 1
Biological|Other|placebo 1
Biological|Other|Radiation 1
Biological|Procedure|Radiation 1
Combination Product|Drug 1
Device|Drug|Procedure|Radiation 1
Device|Genetic|Procedure 1
Device|Procedure 1
Device|Radiation 1
Diagnostic Test|Drug 1
Drug|Genetic|Procedure|Radiation 1
Drug|Other|placebo 1
Drug|Other|placebo|Radiation 1
Other|Radiation 1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country Study_Count
United States 535
France 33
China 24
NA 24
Germany 22
United States|Canada 16
Canada 15
Spain 12
United Kingdom 10
Switzerland 9
Denmark 8
Korea, Republic of 8
Italy 7
Netherlands 7
Japan 5
Sweden 5
Taiwan 5
United States|Australia 5
Australia 4
Belgium 4
Norway 4
United States|Spain 4
United States|Canada|Israel 3
United States|United Kingdom 3
Israel 2
United States|Australia|Austria|Belgium|Canada|Denmark|France|Germany|Israel|Italy|Japan|Netherlands|Norway|Poland|Russian Federation|Spain|Sweden|Switzerland|United Kingdom 2
United States|Germany 2
United States|Puerto Rico 2
Argentina|Belarus|Brazil|Canada|Chile|Estonia|Georgia|India|Indonesia|Ireland|Poland|Thailand|Tunisia|Turkey 1
Australia|Austria|Netherlands 1
Austria 1
Austria|Bulgaria|Canada|Croatia|Estonia|France|Greece|Italy|Latvia|Portugal|Romania|Spain|Sweden|Turkey|United Kingdom 1
Austria|Canada|France|Germany|Italy|Netherlands 1
Austria|France|Germany|Netherlands|Switzerland 1
Austria|France|Greece|Israel|Italy|Netherlands|Portugal|Switzerland 1
Austria|Georgia|Germany|India|Israel|Russian Federation 1
Austria|Germany 1
Austria|Germany|Greece|Italy|Portugal|Romania|Switzerland 1
Austria|Germany|Switzerland 1
Belgium|France|Germany|Italy|Netherlands|Spain|Switzerland|United Kingdom 1
Belgium|France|Italy|Netherlands|Spain|Switzerland 1
Belgium|France|Italy|Netherlands|United Kingdom 1
Belgium|Germany|Italy|Netherlands|Switzerland 1
Belgium|Netherlands 1
Brazil 1
Canada|Germany|Japan|Netherlands 1
Canada|United States 1
Denmark|Finland|Norway|Sweden 1
Denmark|France|Switzerland|United Kingdom 1
Denmark|Germany|Netherlands|Spain|Switzerland 1
Finland 1
France|Germany|Netherlands 1
Germany|Switzerland 1
Germany|United Kingdom 1
Iran, Islamic Republic of 1
Israel|Italy|Netherlands 1
Israel|Italy|Spain|United Kingdom 1
Japan|United States|Australia|Belgium|Canada|Denmark|France|Germany|Greece|Hong Kong|Hungary|Israel|Italy|Korea, Republic of|Netherlands|New Zealand|Poland|Portugal|Romania|Russian Federation|Spain|Sweden|Switzerland|United Kingdom 1
Luxembourg 1
Mexico 1
Mongolia 1
Norway|Sweden 1
Russian Federation 1
Saudi Arabia 1
Serbia 1
Turkey 1
United States|Argentina|Australia|Austria|Belgium|Brazil|Canada|China|Colombia|Czechia|France|Germany|Hong Kong|Ireland|Israel|Italy|Korea, Republic of|Mexico|Netherlands|New Zealand|Portugal|Russian Federation|Singapore|South Africa|Spain|Switzerland|Taiwan|United Kingdom 1
United States|Argentina|Australia|Belgium|Brazil|Canada|Czechia|Denmark|Finland|France|Germany|Israel|Italy|Japan|Netherlands|Russian Federation|Spain|Sweden|Switzerland|United Kingdom 1
United States|Australia|Austria|Belgium|Brazil|Canada|Colombia|Czechia|France|Germany|Greece|Hungary|India|Israel|Italy|Mexico|Netherlands|New Zealand|Peru|Spain|Switzerland|Taiwan|Thailand|United Kingdom 1
United States|Australia|Austria|Belgium|Canada|Czech Republic|France|Germany|Netherlands|United Kingdom 1
United States|Australia|Austria|Belgium|Canada|Czechia|Finland|France|Germany|Hungary|Ireland|Italy|Korea, Republic of|Mexico|Netherlands|Poland|Singapore|Spain|Switzerland|Taiwan|United Kingdom 1
United States|Australia|Austria|Belgium|Canada|France|Germany|India|Italy|Mexico|Netherlands|Poland|Spain|United Kingdom 1
United States|Australia|Austria|Canada|Croatia|Czech Republic|France|Germany|India|Italy|Russian Federation|South Africa|Spain| 1
United States|Australia|Belgium|Canada|France|Germany|Italy|Poland|Spain 1
United States|Australia|Belgium|Canada|France|Spain 1
United States|Australia|Belgium|Canada|Germany|Italy|Spain|United Kingdom 1
United States|Australia|Belgium|Denmark|France|Germany|Italy|Netherlands|Poland|Spain|Switzerland|United Kingdom 1
United States|Australia|Belgium|Netherlands|Spain|Switzerland 1
United States|Australia|Canada 1
United States|Australia|Canada|Chile|France|Germany|Israel|Korea, Republic of|Spain|United Kingdom 1
United States|Australia|Canada|New Zealand|Puerto Rico 1
United States|Australia|Canada|Spain 1
United States|Australia|France|Germany|Netherlands|Spain 1
United States|Australia|France|Korea, Republic of|Spain|United Kingdom 1
United States|Australia|France|Netherlands|Switzerland 1
United States|Australia|Germany|Netherlands|United Kingdom 1
United States|Austria|Belgium|Canada|Denmark|France|Germany|Netherlands|Norway|Spain|Switzerland|United Kingdom 1
United States|Austria|Canada|Czech Republic|France|Germany|Israel|Italy|Korea, Republic of|Spain|Sweden|Switzerland 1
United States|Austria|Czech Republic|France|Germany|Israel|Switzerland 1
United States|Belgium|France|Italy|Spain 1
United States|Canada|France|Germany|Italy|Spain|Switzerland|United Kingdom 1
United States|Canada|Germany|Israel|Netherlands|United Kingdom 1
United States|Canada|Germany|Spain|United Kingdom 1
United States|Canada|Japan|Korea, Republic of|Taiwan 1
United States|Canada|Saudi Arabia 1
United States|Canada|Switzerland 1
United States|Denmark|Netherlands 1
United States|France 1
United States|France|Germany|Spain 1
United States|France|Netherlands 1
United States|France|Spain 1
United States|France|Spain|United Kingdom 1
United States|Germany|Israel 1
United States|India 1
United States|Israel 1
United States|Netherlands 1
United States|Switzerland 1

Sites per Study

Site_count Study_Count
1 447
2 73
3 33
4 41
5 19
6 18
7 21
8 29
9 16
10 18
11 12
12 14
13 9
14 4
15 4
16 4
17 7
18 3
19 5
20 3
21 2
22 5
23 4
24 3
25 2
27 2
28 1
31 1
33 2
34 1
35 1
36 3
38 1
45 1
48 1
52 1
57 1
58 1
60 2
62 2
64 1
65 1
69 1
70 1
82 1
89 1
93 1
98 1
101 1
102 1
104 1
105 1
106 1
110 1
118 1
123 1
125 1
133 1
139 1
152 1
163 1
178 1
180 1
188 1
190 1
204 1
207 1
212 1
214 1
223 1
236 1
237 1
238 1
244 1
257 1
260 1
305 1
308 1
330 1
351 1
400 1
417 1

Phase

Phase Study_Count
Phase 2 319
Phase 1 246
Phase 1/Phase 2 136
N/A 66
Phase 3 47
Early Phase 1 35
Phase 2/Phase 3 8
Phase 4 2

Number of Arms

Number_of_Arms Count_of_Studies
1 434
2 232
3 61
4 20
5 20
6 5
7 2
8 4
10 1
NA 80

Enrollment Metrics by Phase

Measure Early.Phase.1 N.A Phase.1 Phase.1.Phase.2 Phase.2 Phase.2.Phase.3 Phase.3 Phase.4
Min. 3.00000 2.00000 1.00000 5.00000 3.00000 60.000 22.0000 99.00
1st Qu. 10.00000 12.25000 15.00000 27.25000 32.50000 90.000 135.2500 136.75
Median 20.00000 30.00000 25.00000 53.50000 52.00000 215.000 246.0000 174.50
Mean 22.57143 58.77273 36.22727 76.54478 73.42765 291.375 367.2955 174.50
3rd Qu. 30.50000 50.00000 40.00000 92.00000 90.00000 467.500 565.2500 212.25
Max. 70.00000 494.00000 292.00000 515.00000 606.00000 691.000 1173.0000 250.00

Trial Group Type

group_type Group_Count
Experimental 1150
Active Comparator 125
NA 80
Other 42
Placebo Comparator 19
No Intervention 11

Intervention Model

intervention_model Study_Count
Single Group Assignment 509
Parallel Assignment 260
NA 44
Sequential Assignment 40
Crossover Assignment 4
Factorial Assignment 2

Primary Purpose

primary_purpose Study_Count
Treatment 783
Diagnostic 37
Other 10
Supportive Care 10
Basic Science 8
Health Services Research 6
Device Feasibility 3
NA 2

Observational Studies

Studies by Country

Country Study_Count
United States 29
Germany 6
NA 6
China 3
France 3
United Kingdom 3
Italy 2
Korea, Republic of 2
Netherlands 1
Russian Federation 1
Spain 1
Taiwan 1
United States|Austria|Belgium|France|Germany|Greece|Italy|Netherlands|Switzerland 1

Sites per Study

Site_count Study_Count
1 47
2 1
3 2
4 1
6 1
7 1
8 1
10 2
19 1
25 1
50 1

Enrollment Metrics

Measure Observational
Min 1.0000
1st Qu 20.0000
Median 60.0000
Mean 204.9322
3rd Qu 190.0000
Max 3050.0000

Observation Model

observational_model Study_Count
Cohort 30
Case-Only 13
Other 6
Case-Control 5
NA 3
Case Control 2

Time Perspective

time_perspective Study_Count
Prospective 45
Retrospective 9
Cross-Sectional 3
NA 2

Registries

Studies by Country

Country Study_Count
United States 3

Sites per Study

Site_count Study_Count
1 2
8 1

Enrollment Metrics

Measure Registries
Min 48
1st Qu 309
Median 570
Mean 706
3rd Qu 1035
Max 1500

Registry Model

observational_model Study_Count
Cohort 2
Case-Only 1

Time Perspective

time_perspective Study_Count
Prospective 3

Follow-up

target_duration Study_Count
2 Years 2
36 Months 1

Overview of Studies

Interventional Trials

#If less then 500 trials

Observational Studiess

#If less then 500 studies

nct_id brief_title link overall_status source primary_completion_date
NCT03409549 Multi-parametric MRI/Fluorine-18 Fluciclovine PET-CT in Glioblastoma https://ClinicalTrials.gov/show/NCT03409549 Recruiting The Leeds Teaching Hospitals NHS Trust 2020-10-31
NCT03294434 Predicting Sites of Tumour Progression in the Invasive Margin of Glioblastomas (PRaM-GBM Study) https://ClinicalTrials.gov/show/NCT03294434 Recruiting Cambridge University Hospitals NHS Foundation Trust 2020-12-30
NCT03258021 TTFields In GErmany in Routine Clinical Care https://ClinicalTrials.gov/show/NCT03258021 Recruiting NovoCure Ltd. 2021-02-28
NCT03194971 NovoTTF Treatment Signatures in Glioblastoma Patients at Autopsy https://ClinicalTrials.gov/show/NCT03194971 Recruiting Medical College of Wisconsin 2021-05-31
NCT03005132 Integrative Analysis of Human Glioblastoma Multiforme https://ClinicalTrials.gov/show/NCT03005132 Recruiting Shanghai 10th People’s Hospital 2026-12-31
NCT02997423 Cytochrome C Oxidase Activity in Newly Diagnosed Glioblastoma Multiforme (GBM) https://ClinicalTrials.gov/show/NCT02997423 Active, not recruiting University of Iowa 2020-11-30
NCT02899663 MRI Detection of Microbleeds in Glioma Patients https://ClinicalTrials.gov/show/NCT02899663 Completed Fondation Ophtalmologique Adolphe de Rothschild 2015-08-31
NCT02887417 Glioblastoma Platelet Activation Study https://ClinicalTrials.gov/show/NCT02887417 Completed University Medicine Greifswald 2016-10-31
NCT02843230 Monitoring Anti-angiogenic Therapy in Brain Tumors by Advanced MRI https://ClinicalTrials.gov/show/NCT02843230 Recruiting Massachusetts General Hospital 2019-08-31
NCT02725684 Using Genomic Analysis to Guide Individual Treatment in Glioblastoma https://ClinicalTrials.gov/show/NCT02725684 Completed Rockefeller University 2017-07-07
NCT02666066 Radiomics for Prediction of Survival in GBM https://ClinicalTrials.gov/show/NCT02666066 Completed Maastricht Radiation Oncology 2018-01-31
NCT00083512 Collection of Blood and Urine Samples in Patients Receiving Radiation Therapy for Glioblastoma Multiforme https://ClinicalTrials.gov/show/NCT00083512 Recruiting National Institutes of Health Clinical Center (CC) NA
NCT02520635 Supra-early Post-Surgery Chemotherapy in the Treatment on GBM Patients https://ClinicalTrials.gov/show/NCT02520635 Recruiting Beijing Tiantan Hospital 2020-12-31
NCT02473484 Search of Protein Biomarkers in Order to Achieve a Molecular Classification of Gliomas https://ClinicalTrials.gov/show/NCT02473484 Completed University Hospital, Lille 2017-10-31
NCT02458508 Retrospective Evaluation of Melanocortin Receptor 4 Polymorphisms in Patients With GBM Treated With Radiochemotherapy https://ClinicalTrials.gov/show/NCT02458508 Completed University of Pisa 2016-12-31
NCT02375841 Coping With Glioblastoma: A Study of Communication Between Physicians, Patients, and Caregivers https://ClinicalTrials.gov/show/NCT02375841 Recruiting Memorial Sloan Kettering Cancer Center 2021-02-28
NCT02367482 Tryptophan Metabolism in Human Brain Tumors https://ClinicalTrials.gov/show/NCT02367482 Recruiting Wayne State University 2020-12-31
NCT02060890 Molecular Profiling in Guiding Individualized Treatment Plan in Adults With Recurrent/Progressive Glioblastoma https://ClinicalTrials.gov/show/NCT02060890 Completed University of California, San Francisco 2015-09-03
NCT02006563 Metabolic Tumor Volumes in Radiation Treatment of Primary Brain Tumors https://ClinicalTrials.gov/show/NCT02006563 Completed University of Miami 2016-01-31
NCT01880008 Evaluation of FLT PET and MRI as Imaging Biomarkers of Early Treatment Response in Patients With Glioblastoma https://ClinicalTrials.gov/show/NCT01880008 Completed Washington University School of Medicine 2010-02-28
NCT01873469 Impact of [11C]-Methionine PET/MRI for Individual Tailoring Postoperative Radiochemotherapy for Glioblastoma Multiforme https://ClinicalTrials.gov/show/NCT01873469 Completed Technische Universität Dresden 2017-10-31
NCT01849952 Evaluating the Expression Levels of MicroRNA-10b in Patients With Gliomas https://ClinicalTrials.gov/show/NCT01849952 Recruiting Dartmouth-Hitchcock Medical Center 2022-05-31
NCT01712542 Curcumin Bioavailability in Glioblastoma Patients https://ClinicalTrials.gov/show/NCT01712542 Completed Johann Wolfgang Goethe University Hospital 2013-05-31
NCT01618747 An Observational Study of Avastin (Bevacizumab) in Patients With Glioblastoma Multiforme in First or Second Relapse https://ClinicalTrials.gov/show/NCT01618747 Completed Hoffmann-La Roche 2015-12-24
NCT01604590 Imaging Biomarkers of Tissue Microstructure and Vasculature as Predictors of Glioblastoma Multiforme https://ClinicalTrials.gov/show/NCT01604590 Completed Medical University of South Carolina 2014-06-30
NCT01598597 An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite) https://ClinicalTrials.gov/show/NCT01598597 Completed Genentech, Inc. 2014-11-30
NCT01516905 PET/CT Imaging of Malignant Brain Tumors With 124I-NM404 https://ClinicalTrials.gov/show/NCT01516905 Completed University of Wisconsin, Madison 2016-05-17
NCT01493219 Biomarkers for Prognosis of Glioblastoma (GBM) https://ClinicalTrials.gov/show/NCT01493219 Completed University of Nebraska 2017-09-30
NCT01345370 Comparison of Different Methods to Test MGMT Status in Glioblastoma Patients https://ClinicalTrials.gov/show/NCT01345370 Completed Center Eugene Marquis 2015-04-30
NCT04359745 Improving Treatment of Glioblastoma: Distinguishing Progression From Pseudoprogression https://ClinicalTrials.gov/show/NCT04359745 Recruiting Guy’s and St Thomas’ NHS Foundation Trust 2023-05-26
NCT04313842 A Explorative Study to Evaluate the Clinical Feasibility of AVATAMED https://ClinicalTrials.gov/show/NCT04313842 Recruiting Samsung Medical Center 2021-06-01
NCT04171895 Communication Training for Caregivers In Advanced Care Planning https://ClinicalTrials.gov/show/NCT04171895 Recruiting Memorial Sloan Kettering Cancer Center 2021-10-31
NCT04180046 Utility of Primary Glioblastoma Cell Lines https://ClinicalTrials.gov/show/NCT04180046 Active, not recruiting Neuromed IRCCS 2019-06-26
NCT04143425 Response Prediction for Anti-angiogenic Treatment in Recurrent Glioblastoma https://ClinicalTrials.gov/show/NCT04143425 Recruiting Asan Medical Center 2022-06-30
NCT03939858 Bioenergetic Profiling and Cognition in GBM Patients https://ClinicalTrials.gov/show/NCT03939858 Recruiting Wake Forest University Health Sciences 2020-08-31
NCT03900689 Social Determinants of Health in Glioblastoma Population https://ClinicalTrials.gov/show/NCT03900689 Recruiting Wake Forest University Health Sciences 2021-05-31
NCT03877861 Validation of Readibandâ„¢ Actigraph and Associated Sleep/Wake Classification Algorithms https://ClinicalTrials.gov/show/NCT03877861 Recruiting Allina Health System 2020-12-31
NCT03865355 Blood and Cerebrospinal Fluid Metabolomic Profile in Glioma Patients https://ClinicalTrials.gov/show/NCT03865355 Recruiting Novosibirsk State University 2024-04-11
NCT03770468 Molecular Genetic, Host-derived and Clinical Determinants of Long-term Survival in Glioblastoma https://ClinicalTrials.gov/show/NCT03770468 Recruiting European Organisation for Research and Treatment of Cancer - EORTC 2021-12-31
NCT03687099 Immunological and Functional Characterization of Cellular Population CD45+ Infiltrating Human Glioblastoma https://ClinicalTrials.gov/show/NCT03687099 Recruiting Centre Hospitalier Universitaire, Amiens 2019-07-30
NCT03623347 Upfront Bevacizumab/témozolomide for Gliomastomas With Neurological Impairment https://ClinicalTrials.gov/show/NCT03623347 Completed Centre Hospitalier Universitaire, Amiens 2017-05-12
NCT03593993 A Biospecimen Collection Study in BRAF-V600E Mutated Recurrent Gliomas https://ClinicalTrials.gov/show/NCT03593993 Recruiting Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 2021-05-19
NCT03567135 Temozolomide Plus Anti-angiogenesis Drugs and Radiotherapy as a Treatment for Glioblastoma https://ClinicalTrials.gov/show/NCT03567135 Recruiting Fuzhou General Hospital 2019-04-01
NCT03439332 Multicentre Validation of How Vascular Biomarkers From Tumor Can Predict the Survival of the Patient With Glioblastoma https://ClinicalTrials.gov/show/NCT03439332 Completed Universitat Politècnica de València 2018-07-01
NCT02022384 Immunophenotyping From Blood of Patients With Malignant Gliomas https://ClinicalTrials.gov/show/NCT02022384 Recruiting University of Erlangen-Nürnberg Medical School 2020-12-31
NCT01135875 Laboratory Study of Early Tumor Markers in the Peripheral Blood of Glioblastoma Multiforme Patients https://ClinicalTrials.gov/show/NCT01135875 Completed University of Florida 2013-04-30
NCT01124461 BIRN (Biomedical Informatics Research Network) Resources Facilitate the Personalization of Malignant Brain Tumor https://ClinicalTrials.gov/show/NCT01124461 Completed Washington University School of Medicine 2017-11-30
NCT01089868 Usefulness of Therapy Monitoring by Means of [(18)F]Fluoroethyltyrosine-Positron Emission Tomography (FET-PET) in Glioblastoma Multiforme Patients https://ClinicalTrials.gov/show/NCT01089868 Completed Ludwig-Maximilians - University of Munich 2011-06-30
NCT00973557 The Effect of Monoclonal Vascular Endothelial Growth Factor (VEGF) Antibody (Bevacizumab) on Pituitary Function https://ClinicalTrials.gov/show/NCT00973557 Completed Cedars-Sinai Medical Center 2011-09-30
NCT00897663 Improving the Selection of Patients With Glioblastoma Multiforme for Treatment With Epidermal Growth Factor Receptor Inhibitor Therapies https://ClinicalTrials.gov/show/NCT00897663 Completed Alliance for Clinical Trials in Oncology 2018-01-31
NCT03896958 The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology) https://ClinicalTrials.gov/show/NCT03896958 Recruiting SpeciCare 2021-03-12
NCT02905643 Discerning Pseudoprogression vs True Tumor Growth in GBMs https://ClinicalTrials.gov/show/NCT02905643 Completed Ascension St. Vincent 2018-02-13
NCT00777686 Measuring Non-Enhancing Glioblastoma Progression https://ClinicalTrials.gov/show/NCT00777686 Completed M.D. Anderson Cancer Center 2011-03-31
NCT00723827 Temodal (Temozolomide) Post Marketing Surveillance Protocol (Study P05557AM2) https://ClinicalTrials.gov/show/NCT00723827 Completed Merck Sharp & Dohme Corp. 2011-09-30
NCT00725010 Temozolomide in Concomitant Radiochemotherapy Followed by Sequential Temozolomide Chemotherapy - Observational Program (Study P04816) https://ClinicalTrials.gov/show/NCT00725010 Completed Merck Sharp & Dohme Corp. 2009-04-30
NCT00704808 Post Marketing Surveillance: Newly Diagnosed Glioblastoma Multiforme Treated With Radiotherapy/Temozolomide and Adjuvant Temozolomide (Study P04739) https://ClinicalTrials.gov/show/NCT00704808 Completed Merck Sharp & Dohme Corp. 2008-12-31
NCT00001171 Evaluation of Factors in Human Brain Tumors https://ClinicalTrials.gov/show/NCT00001171 Completed National Institutes of Health Clinical Center (CC) NA
NCT00009035 Natural History of Patients With Brain and Spinal Cord Tumors https://ClinicalTrials.gov/show/NCT00009035 Completed National Institutes of Health Clinical Center (CC) NA
NCT00001148 Detecting Malignant Brain Tumor Cells in the Bloodstream During Surgery to Remove the Tumor https://ClinicalTrials.gov/show/NCT00001148 Completed National Institutes of Health Clinical Center (CC) NA

Registries

#If less then 500 registries

nct_id brief_title link overall_status source primary_completion_date
NCT03642080 MRI Predictors of Response to Tumor Treating Fields https://ClinicalTrials.gov/show/NCT03642080 Recruiting New York Methodist Hospital 2021-09-30
NCT03561207 3D Prediction of Patient-Specific Response https://ClinicalTrials.gov/show/NCT03561207 Recruiting KIYATEC 2024-06-30
NCT03452774 SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry https://ClinicalTrials.gov/show/NCT03452774 Recruiting Massive Bio, Inc. 2021-12-31